Bimekizumab
Bimzelx (bimekizumab) is an antibody pharmaceutical. Bimekizumab was first approved as Bimzelx on 2021-08-20. It has been approved in Europe to treat psoriasis. The pharmaceutical is active against interleukin-17A and interleukin-17F.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 5 | 7 | 2 | — | 15 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | 2 | 6 | 1 | — | 10 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 3 | 2 | — | — | 5 |
| Hidradenitis suppurativa | D017497 | L73.2 | — | 1 | 3 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BIMEKIZUMAB |
| INN | bimekizumab |
| Description | Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque psoriasis.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297700 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 09495UIM6V (ChemIDplus, GSRS) |
Target
Agency Approved
IL17A
IL17A
IL17F
IL17F
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 403 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more